It's How Medicine Should Be®
<< Previous | New Search | Return to Search Results | Next >>

Physician Profile


call (888) 352-RUSH for help arranging an appointment

John M. Zajecka, MD

  • Psychiatry
Board Certification:
  • Psychiatry
  • Neurology
Faculty Rank: Associate Professor
Medical or Graduate Education: Loyola University Chicago Stritch School of Medicine
Residency: Rush University Medical Center - Psychiatry
Clinical Expertise:
  • Bipolar disorder
  • Depression
  • Mood disorders
  • Psychopharmacology and clinical research
  • Psychotic disorders
  • Sexual dysfunction
  • Vagus nerve stimulation
Research Interests:
  • Psychotherapy and pharmacological treatments for depression
  • Bipolar disorder
  • Psychosis
Google Map
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to Listings go back five years.

  1. The pro-inflammatory profile of depressed patients is (partly) related to obesity.
    Shelton RC, Falola M, Li L, Zajecka J, Fava M, Papakostas GI
    J Psychiatr Res
    2015 Nov
  2. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
    Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS
    2015 Feb 17
  3. Effect of Cognitive Therapy With Antidepressant Medications vs Antidepressants Alone on the Rate of Recovery in Major Depressive Disorder: A Randomized Clinical Trial.
    Hollon SD, DeRubeis RJ, Fawcett J, Amsterdam JD, Shelton RC, Zajecka J, Young PR, Gallop R
    JAMA Psychiatry
    2014 Oct 1
  4. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial.
    Papakostas GI, Shelton RC, Zajecka JM, Bottiglieri T, Roffman J, Cassiello C, Stahl SM, Fava M
    J Clin Psychiatry
    2014 Apr 15
  5. Residual symptoms in major depressive disorder: prevalence, effects, and management.
    Zajecka J, Kornstein SG, Blier P.
    J Clin Psychiatry. 2013
    2013 Apr
    74(4):407-14. doi: 10.4088/JCP.12059ah1. Review. No abstract available.
  6. Residual symptoms and relapse: mood, cognitive symptoms, and sleep disturbances.
    Zajecka JM
    J Clin Psychiatry
    74 Suppl 2:9-13.
  7. l-Methylfolate as Adjunctive Therapy for SSRI-Resistant Major Depression: Results of Two Randomized, Double-Blind, Parallel-Sequential Trials.
    Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, Baer L, Dalton ED, Sacco GR, Schoenfeld D, Pencina M, Meisner A, Bottiglieri T, Nelson E, Mischoulon D, Alpert JE, Barbee JG, Zisook S, Fava M.
    Am J Psychiatry. 2012
    2012 Dec 1
    169(12):1267-74. doi: 10.1176/appi.ajp.2012.11071114.
  8. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.
    Papakostas GI, Vitolo OV, Ishak WW, Rapaport MH, Zajecka JM, Kinrys G, Mischoulon D, Lipkin SH, Hails KA, Abrams J, Ward SG, Meisner A, Schoenfeld DA, Shelton RC, Winokur A, Okasha MS, Bari MA, Fava M.
    J Clin Psychiatry. 2012
    2012 Dec
    73(12):1541-7. doi: 10.4088/JCP.12m07670.
  9. The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression.
    DeBattista C, Kinrys G, Hoffman D, Goldstein C, Zajecka J, Kocsis J, Teicher M, Potkin S, Preda A, Multani G, Brandt L, Schiller M, Iosifescu D, Fava M.
    J Psychiatr Res. 2011
    2011 Jan
    45(1):64-75. doi: 10.1016/j.jpsychires.2010.05.009. Epub 2010 Jul 3.
  10. Evidence for the use of l-methylfolate combined with antidepressants in MDD.
    Fava M, Shelton RC, Zajecka JM.
    J Clin Psychiatry. 2011
    2011 Aug
    72(8):e25. doi: 10.4088/JCP.11012tx1c.
  11. Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release.
    Trivedi MH, Dunner DL, Kornstein SG, Thase ME, Zajecka JM, Rothschild AJ, Friedman ES, Shelton RC, Keller MB, Kocsis JH, Gelenberg A.
    J Affect Disord. 2010
    2010 Nov
    126(3):420-9. doi: 10.1016/j.jad.2010.04.011. Epub 2010 May 26.
  12. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial.
    Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A.
    J Clin Psychopharmacol. 2010
    2010 Apr
    30(2):135-44. doi: 10.1097/JCP.0b013e3181d420a7.
  13. Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study.
    Rothschild AJ, Dunlop BW, Dunner DL, Friedman ES, Gelenberg A, Holland P, Kocsis JH, Kornstein SG, Shelton R, Trivedi MH, Zajecka JM, Goldstein C, Thase ME, Pedersen R, Keller MB.
    Psychopharmacol Bull. 2009
  14. Oral divalproex sodium loading for adolescent outpatients with acute mania/hypomania: a report of 2 cases.
    Zajecka JM, Gutierrez SN.
    J Clin Psychiatry. 2008
    2008 Jun
    69(6):1016-8. No abstract available.
  • (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript